Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
13th December 2007

Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
30th November 2007

1. Chroma Progresses Novel Cancer Therapy CHR-2797 Into Phase II Solid Tumour Study
13th June 2007

2. Appointment of Klaus Veitinger as Non-Executive Director
22nd May 2007

3. CHR-2797 enters Phase II development
26th March 2007

4. Chroma raises $53m in Series C financing
3rd April 2006

5. Discovery Partners International, Inc. and Chroma Therapeutics Enter Into Collaboration For Lead Identification On Multiple Targets
25th March 2005

6. Chroma Therapeutics Ltd completes further financing round; raises £5m from major US healthcare investor
7th December 2004

7. First patient treated in Phase I study of CHR-2797 in cancer
16th November 2004

8. Chroma Therapeutics Ltd further strengthens its Management Team with the appointments of Chief Financial Officer and Chief Medical Officer
21st October 2004

9. Chroma Therapeutics Ltd completes £10m Series B financing and announces appointment of Peter Allen and Petri Vainio as non executive directors
14th June 2004

10. Appointment of Ian Nicholson as Chief Executive and Raj Parekh as Chairman
11th May 2004